SCHEMBL720515

SCHEMBL720515

Cc1c(C(O)C2CCCCC2)oc2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
CYP2C19 P33261 1/20 0.45
VKORC1 Q9BQB6 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HTT P42858 2/20 0.42
RECQL P46063 2/20 0.42
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.42
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
KDM4E B2RXH2 2/20 0.39
LMNA P02545 2/20 0.39
CYP2D6 P10635 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38
CHRM5 P08912 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
MAPT P10636 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL717053 0.84 NPC1 (0.45) NPC1RAB9AALDH1A1KMT2A
SCHEMBL716824 0.82 NPC1 (0.48) NPC1RAB9ACYP2C19VKORC1ALDH1A1
SCHEMBL721039 0.81 NPC1 (0.44) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL720875 0.81 RAB9A (0.46) NPC1RAB9AALDH1A1HPGDTSHR
SCHEMBL718925 0.81 NPC1 (0.55) NPC1RAB9ACYP2C19ALDH1A1KMT2A
SCHEMBL721192 0.81 MCL1 (0.45) NPC1RAB9AALDH1A1KMT2AMAPT
SCHEMBL721493 0.79 RAB9A (0.34) NPC1RAB9ACYP2C19VKORC1ALDH1A1
SCHEMBL718548 0.79 RAB9A (0.53) NPC1RAB9ACYP2C19ALDH1A1HTT
SCHEMBL718063 0.79 RAB9A (0.57) NPC1RAB9AALDH1A1HPGDMEN1
SCHEMBL716447 0.78 NPC1 (0.37) NPC1RAB9AALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885RAB9A 2454/4885CYP2C19 946/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885RAB9A 2454/4885CYP2C19 946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.